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Abstract: The wide tissue distribution of the adrenergic β3 receptor makes it a potential target
for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder
(OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the
treatment of OAB. In the present study, we have carried out an extensive structure-activity relationship
analysis of a series of 41 aryloxypropanolamine compounds based on three-dimensional quantitative
structure-activity relationship (3D-QSAR) techniques. This is the first combined comparative
molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA)
study in a series of selective aryloxypropanolamines displaying anti-diabetes and anti-obesity
pharmacological profiles. The best CoMFA and CoMSIA models presented values of r2ncv = 0.993
and 0.984 and values of r2test = 0.865 and 0.918, respectively. The results obtained were subjected to
extensive external validation (q2, r2, r2m, etc.) and a final series of compounds was designed and their
biological activity was predicted (best pEC50 = 8.561).
Keywords: β3-adrenergic receptor; obesity; diabetes; overactive bladder; aryloxypropanolamines;
mirabegron; vibegron; 3D-QSAR; CoMFA; CoMSIA
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1. Introduction
The β3 adrenergic receptor (β3-AR) is a transmembrane protein that belongs to the superfamily
of G protein-coupled receptors [1,2]. There are three subtypes of β adrenergic receptors. The β1
adrenergic receptor is mainly located in the cardiovascular system, where it is the target of selective
blockers such as atenolol or bisoprolol, which are used for the treatment of hypertension [3]. The β2
adrenergic receptor is mainly located in smooth muscles, where their activation by agonists such
as salbutamol or salmeterol enables asthma treatment [4]. On the other hand, the β3-AR is widely
distributed in the human body. It is present in the brain [5], the cardiovascular system [6], colon,
bladder, and adipose tissue [7]. Therefore, it could be a therapeutic target for the treatment of diseases
such as depression [8], hypertension, heart failure [9], overactive bladder (OAB) syndrome [10],
colon cancer [11], metabolic syndrome, and obesity [12].
Until now, the pharmacophore for the design and synthesis of new β3-AR ligands has been the
ethanolamine chain. Most of the compounds are of the phenylethanolamine or aryloxypropanol-amine
type. To achieve β3 adrenergic selectivity, the insertion of bulky groups on the right-hand side (RHS) of
the molecule is favorable (Figure 1). However, since the approval of mirabegron in 2012, few selective
agonist compounds for theβ3-AR receptor have been reported [13–15]. Selectiveβ3 adrenergic agonists
include CL 316,243 [16], amibegron (SR58611A) [17,18], mirabegron (YM-178) [10], and vibegron
(RVT-901) [19] (Figure 1). CL 316,243 has anti-obesity and anti-diabetic profiles [20]. Amibegron
presents antidepressant effects in animal models [21]. Mirabegron is the only selective β3 drug
currently approved by the U.S. Food and Drug Administration for the treatment of OAB syndrome [22],
however, there have been reports of upper airway angioedema following the administration of
mirabegron [23]. On the other hand, recent studies have shown that mirabegron raises blood pressure
and prolongs the QTc interval in electrocardiograms [24]. This information calls into question the
continuity of mirabegron in the market. In this scenario, Merck Laboratories reported in 2016 the
discovery of vibegron (Figure 1), a new potent and selective β3-AR agonist, which is currently under
development in human clinical trials for the treatment of OAB [19].
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From the works of Cramer and Klebe [25,26], comparative molecular field analysis (CoMFA)
and comparative molecular similarity index analysis (CoMSIA) are considered useful methodologies
to understand the pharmacological properties of a series of compounds. Contour maps generated
from CoMFA and CoMSIA show regions of the molecular structure where modifications in the
steric, electrostatic, hydrophobic, and H-bond properties generate a favorable or unfavorable change
in biological activity. Therefore, the contour maps obtained help to: (a) understand the nature
of ligand-receptor interactions; (b) predict biological activity; and (c) aid in the rational design of
new compounds.
In the last 10 years, there have been only two reports of quantitative structure-activity relationship
(QSAR) studies on selective compounds for the β3-AR [27,28], one of which was conducted by
our research group [28]. In both cases, the studies were carried out on phenylethanolamine-type
compounds. Since then, there have been no reports of QSAR studies on aryloxypropanolamines.
In the present work, we present a three-dimensional (3D)-QSAR study of a series of potent
and selective human β3-AR agonists [29,30]. The reported compounds showed an interesting
profile as potential drugs for the treatment of obesity and noninsulin-dependent (type II) diabetes.
The compounds have a wide structural variability on both the RHS and left-hand side (LHS) of the
general aryloxypropanolamine structure (Figure 1). The information obtained from the CoMFA and
CoMSIA contour maps was systematized in a useful structural-activity relationship diagram. With this
information, we finally reported the design of new compounds with promising β3 adrenergic activity.
2. Results and Discussion
2.1. Statistical Results
A summary of the statistical results for CoMFA and CoMSIA are presented in Table 1. Details of
all possible combinations are given in Table S1 (Supplementary Material).
Table 1. Statistical parameters and Field combinations for CoMFA and CoMSIA a.
Model q2 N SEP SEE r2ncv F r2 Field Contributions
S E H D A
CoMFA-SE 0.537 6 0.544 0.067 0.993 525.4 0.865 0.412 0.588
CoMSIA-SE 0.566 7 0.539 0.101 0.985 193.0 0.002 0.299 0.701
CoMSIA-SEHA 0.674 6 0.456 0.119 0.978 161.3 0.790 0.174 0.335 0.215 0.276
CoMSIA-SEA 0.651 5 0.462 0.151 0.963 118.7 0.760 0.245 0.395 0.360
CoMSIA-SEDA 0.601 7 0.517 0.103 0.984 185.5 0.816 0.229 0.324 0.190 0.257
CoMSIA-SD 0.551 6 0.536 0.217 0.926 46.2 0.347 0.470 0.530
CoMSIA-SHD 0.561 9 0.570 0.095 0.988 172.1 0.237 0.312 0.398 0.289
CoMSIA-EHA 0.598 6 0.507 0.136 0.971 123.0 0.765 0.427 0.299 0.274
CoMSIA-EHDA 0.508 7 0.574 0.111 0.982 160.3 0.716 0.375 0.261 0.156 0.208
CoMSIA-ALL 0.669 6 0.460 0.101 0.984 225.9 0.918 0.165 0.279 0.181 0.159 0.215
a q2 = the square of the leave-one-out (LOO) cross-validation (CV) coefficient; N = the optimum number of
components; SEP = standard error of prediction; SEE is the standard error of estimation of non-CV analysis;
r2ncv is the square of the non CV coefficient; F is the F-test value; r2 is the predictive r2 for test set compounds;
S, E, H, D and A are the steric, electrostatic, hydrophobic, hydrogen-bond donor, and hydrogen-bond acceptor
contributions respectively.
The best models were searched through successive field combinations. The first parameter
to evaluate the statistical robustness of a QSAR model is the value of q2, which must be greater
than 0.5. q2 is an indicator of the internal predictive capacity of a QSAR model. For CoMFA, the
model that considered both field contributions (CoMFA-SE) presented the highest value (0.537), while
with CoMSIA, several models presented a significant q2 value. The CoMSIA steric + electrostatic +
hydrophobic + acceptor (CoMSIA-SEHA) and CoMSIA steric + electrostatic + acceptor (CoMSIA-SEA)
models generated similar values for this coefficient (0.674 and 0.651, respectively). However, the value
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of r2, which evaluates the external predictive capacity of the model, allowed for discrimination between
the models. In this case, the CoMSIA model that considered all the field contributions (CoMSIA-All)
presented the highest value of r2 (0.918). The best models also had a low SEE and a high r2. The optimal
number of components (N) is also low in all models presented (N = 6 for the best CoMFA and CoMSIA
model). Ideally, a good model should have as few components as possible (N should be less than
one-third of the total number of compounds studied), which ensures that the predictions will be based
on meaningful information from field contributions, rather than on overtraining of the model. There is
also a balance in the percentages of field contribution (approximately 50% for each field in CoMFA-SE
and approximately 20% for each field in CoMSIA-All), which supports the reliability of the conclusions
obtained from each contour map.
Table 2 presents a summary of the external validation of the CoMFA-SE and CoMSIA-All models
(hereafter they are referred to as “CoMFA” and “CoMSIA” models). Both models have a high value
for r2 (0.865 and 0.918, respectively), which is an indication of an adequate external predictive capacity.
However, according to Golbraikh and Tropsha [31,32], high values of q2 and r2 (conditions 1 and 2)
are necessary but not sufficient conditions for the validation of a model. For a QSAR model to have
a reliable predictive capability, the line for experimental versus predicted activity should be as close
as possible to the line y = x. This is observed in the fulfillment of conditions 3a or 3b, 4a or 4b, 5a or
5b, and 6 listed in Table 2. Finally, condition 7, known as r2m metrics, is a quantitative measure to
determine the proximity between the observed and the predicted activity for the test set. The CoMFA
and CoMSIA models reported here fulfilled all the conditions for internal and external validation and,
in general, the CoMSIA model displays better statistical parameters than CoMFA.
Table 2. Summary of external validation parameters for CoMFA and CoMSIA.
Condition Parameters Threshold Value CoMFA CoMSIA
1 q2 >0.5 0.537 0.669
2 r2 >0.6 0.865 0.918
3a r20 Close to value of r
2 0.864 0.911
3b r′20 Close to value of r2 0.834 0.885
4a k 0.85 < k < 1.15 1.002 0.996
4b k′ 0.85 < k′ < 1.15 0.937 1.004
5a
(
r2 − r20
)
/r2 <0.1 0.001 0.007
5b
(
r2 − r′20
)
/r2 <0.1 0.036 0.034
6
∣∣∣r20 − r′20∣∣∣ <0.3 0.031 0.027
7 r2m >0.5 0.793 0.843
q2 and r2 are the same parameters as listed in Table 1; r20 and k are the correlation coefficient between the experimental
(x) versus predicted activities (y) for test set through the origin and the respective slope of regression; and r′20 and k′
are the correlation coefficient between the predicted (y) versus experimental activities (x) for test set through the
origin and the respective slope of regression. r2m was defined in Equation (6).
The values of experimental activity, predicted activity, and residual values for the best CoMFA and
CoMSIA models are shown in Table 3. All the compounds showed low residual values and deviations
in the predicted activity over a logarithmic unit were not observed. Figure 2A,B show the graphs of
experimental versus predicted activity, from which it can be seen that the data distribution is close to
the y = x line. Both models show a good balance in terms of predictive capacity. The CoMFA model
presents 21 compounds with negative residual values and 20 with positive deviations (Figure 2C),
while the CoMSIA model presents 19 compounds with negative residual values and 22 with positive
deviations (Figure 2D). The residual ranges were −0.44 to 0.45 for CoMFA and −0.53 to 0.37 for
CoMSIA. As shown in Figure 2E,F, the CoMFA and CoMSIA models show a satisfactory predictive
capability throughout the whole set of data (training and test set) as well as a good predictive power
for both, less active (8, 20, and 21) and most active compounds (16, 32, and 33).
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Table 3. Experimental and predicted pEC50 and residual values for analyzed compounds according to
CoMFA and CoMSIA.
CoMFA CoMSIA
Molecule Experimental pEC50 Predicted pEC50 Residual Predicted pEC50 Residual
1 t 6.538 6.263 0.27 6.435 0.10
2 6.745 6.760 −0.02 6.743 0.00
3 6.553 6.532 0.02 6.552 0.00
4 6.602 6.610 −0.01 6.596 0.01
5 6.482 6.494 −0.01 6.496 −0.01
6 t 6.553 6.811 −0.26 6.444 0.11
7 5.602 5.559 0.04 5.635 −0.03
8 t 5.018 4.969 0.05 4.646 0.37
9 6.187 6.205 −0.02 6.197 −0.01
10 t 6.745 6.761 −0.02 6.651 0.09
11 t 6.854 7.136 −0.28 6.830 0.02
12 6.886 6.893 −0.01 6.965 −0.08
13 6.569 6.667 −0.10 6.721 −0.15
14 t 6.721 6.707 0.01 6.826 −0.10
15 6.585 6.601 −0.02 6.569 0.02
16 7.208 7.144 0.06 6.953 0.26
17 6.553 6.530 0.02 6.632 −0.08
18 t,a 6.301 5.853 0.45 6.601 −0.30
19 5.699 5.636 0.06 5.613 0.09
20 4.921 5.049 −0.13 4.908 0.01
21 3.886 3.794 0.09 3.894 −0.01
22 5.032 5.157 −0.13 4.980 0.05
23 t,a 5.721 6.157 −0.44 5.908 −0.19
24 6.357 6.362 −0.01 6.549 −0.19
25 5.854 5.818 0.04 5.979 −0.13
26 6.328 6.331 0.00 6.345 −0.02
27 6.292 6.269 0.02 6.303 −0.01
28 6.398 6.288 0.11 6.404 −0.01
29 6.569 6.604 −0.04 6.605 −0.04
30 6.553 6.601 −0.05 6.534 0.02
31 6.469 6.539 −0.07 6.403 0.07
32 7.000 6.984 0.02 6.964 0.04
33 7.000 6.921 0.08 6.904 0.10
34 t 6.569 6.244 0.32 6.539 0.03
35 6.796 6.835 −0.04 6.710 0.09
36 6.699 6.696 0.00 6.572 0.13
37 t 6.638 6.503 0.14 6.448 0.19
38 6.638 6.570 0.07 6.601 0.04
39 6.770 6.781 −0.01 6.902 −0.13
40 t,b 6.495 6.678 −0.18 6.910 −0.42
41 t,b 6.187 6.390 −0.20 6.718 −0.53
t Test set compounds; a CoMFA outliers; b CoMSIA outliers.
Furthermore, to assess the robustness of the model, the Y-randomization test [33] was applied
(see Table S2 of the Supplementary Material for randomizations). The dependent variable (biological
activity) was randomly shuffled and a new QSAR model was developed using the original independent
variable matrix. If after multiple randomizations the new values of q2 and r2ncv are negative or below
the limit of acceptability (q2 < 0.5, r2ncv < 0.6), then it is corroborated that the results obtained in the
formulation of the final models are not by chance. In our case, the new QSAR models (after several
repetitions) have low q2 and r2ncv values (Table 4).
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In summary, the best CoMFA and CoMSIA models were selected based on their statistical
robustness and good validated external predictability. In the case of CoMFA, both potentials contribute
equally to biological activity (41.2% for the steric field and 58.8% for the electrostatic field). In the case of
CoMSIA there is a homogeneous contribution of each field to the activity, however, the electrostatic field
presents a slightly higher contribution (27.9%), so its contribution to biological activity is more important.
2.2. Contour Maps Analysis
2.2.1. CoMFA
In the electrostatic contour map (Figure 3A), we can see a blue polyhedron around the methylene
connector that connects the amide with imidazole ring. This suggests that the replacement of this
connector by electropositive groups would be favorable for activity. For example, groups such as
CONH, CO(NH)2, or a protonated amino group (projecting the proton towards the blue polyhedron)
could be evaluated. This could explain why compounds 32 and 33 are among the most active since
they project the polar proton of the urea function towards the blue zone, while compounds 8 and 20
present low activities due to the absence of said function. On the other hand, as seen in Figure 3B, the
most inactive compound of the series (compound 21) intersects the blue polyhedron. Therefore, one
way to improve the activity of this type of derivative would be to increase the electronic deficiency of
the benzene ring. This could be achieved by inserting electronic attractor groups into the ring or by
inserting groups such as OH or NH that project the hydrogen atom to the blue region.
In the steric contour map around the most active compound 16 (Figure 3C), a green polyhedron
is seen around position 5 of the imidazole ring. Therefore, the insertion of bulky substituents in that
position would be favorable. This could explain the high activities reported for compounds 12 and 32,
which project a benzyl and nitro group, respectively, to the green region. In Table 5, the proposals 1x to
5x were based on this observation. These compounds contain OH, NH, F, and acetyl groups in that
position. The use of more voluminous halogens did not generate better predictions (e.g., Cl, Br, or I).
On the other hand, in the less active compounds 7, 20, and 21 (Figure 3D), the benzene ring intersects
the yellow region, which could explain the low activity of these compounds.
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21 (right), the most active and less active of the series respectively. Electropositive favored (blue) and
electronegative favored (red). Sterically favored (green) and disfavored (yellow).
2.2.2. CoMSIA
The CoMSIA electrostatic contour map (Figure 4A,B) is similar to that obtained for CoMFA
(Figure 3A,B). A blue polyhedron is visible near the methylene linker (Figure 4A). The concordance of
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this information in both models led us to propose the insertion of a urea group, after which we obtained
derivatives with high predicted activity (Table 5). As in CoMFA, the less active compound 21 intersects
the blue polyhedron in the benzene region, therefore the insertion of electropositive functions before
the ring would be most favorable for activity.
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Like the CoMFA map (Figure 3C), the steric contour map shows a green region intersecting
position 5 of the imidazole ring of compound 16 (Figure 4C). However, on the CoMSIA map,
a yellow region surrounds the green region, therefore the increase in volume should be explored
with caution. In fact, in the proposal for new structures, it was found that the insertion of large groups
in position 5, such as Br and Cl, generated a reduction in biological activity, however, the insertion of
medium-volume groups such as OH, NH2, and F improved activity considerably. This also suggests
that the increase in molar refractivity is not favorable for activity.
The hydrophobic contour map (Figure 4E,F) shows two yellow polyhedrons, one near the carbonyl
oxygen and the other near the benzene ring. This indicates that the presence of lipophilic groups in
these regions would be favorable for activity. The high activity reported for compounds 32, 33, 35,
and 39 could be explained by this fact since they position the sulfur atom of the sulfonylurea linker
towards the smaller yellow polyhedron. In addition, in those same derivatives, the proton of the NH
group at the right of the connector is directly positioned towards a grey polyhedron, which suggests
that the presence of hydrophilic groups in that area is favorable. On the other hand, around the most
active compound 16, there is a second grey polyhedron intersecting the imidazole ring (Figure 4E),
which implies that this ring could be replaced by other hydrophilic isostere rings, but not by systems
such as benzene or thiophene. Finally, the second yellow polyhedron intersects the benzene ring of the
most active compound 16, but not the benzene ring of the least active compounds 19–23 (Figure 4F),
which may in part explain the lower activity observed for these derivatives.
A large purple polyhedron surrounding the imidazole ring and the ortho position of benzene
around the most active compound 16 (Figure 4G) is shown on the H-bond donor map (Figure 4G,H),
suggesting that the presence of H-bond donor groups in these positions is not favorable for activity.
This may explain the low activity of compound 8 (which is among the series of compounds 5–18) because
it directly positions the NH group of the imidazole ring to the upper purple region. On the other hand,
a smaller cyan polyhedron in the lower area suggests that the selective insertion of H-bond donor groups
in the methylene connector area of imidazole would be beneficial. This is corroborated by the fact
that the most active compounds 32, 33, and 35 position the NH group of the sulfonylurea towards this
polyhedron. Finally, a small purple polyhedron on the LHS of the molecule suggests that the presence of
NH groups of the dihydrobenzimidazolone and indole ring systems would not be beneficial for activity.
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The H-bond acceptor contour map (Figure 4I,J) shows two magenta polyhedra close to position
3 and 5 of the imidazole ring, which means that incorporation of H-bond acceptor atoms in these
positions is favorable. In fact, compounds 32 and 33 position the oxygen atoms from nitro groups to
the magenta region. Other groups that could be inserted are F, OH, and pyridine rings.
2.3. Outliers
In the CoMFA model, compounds 18 and 23 were outliers. Compound 18 has a pEC50 = 6.3010 and
unlike its analog 16 (the most active compound in the series), it has an alkylation in the N of the amide.
Therefore, the spatial conformation of the imidazole ring may be altered. On the other hand, alkylation
of the ethyl chain in compound 18 restricts rotation and could fix a different conformation within the
target. With respect to the underestimation of activity for compound 23, this may be because CoMFA
does not consider the favorable effects of the presence of the urea group. Effects that are considered by
the hydrophobic and H-bond acceptor maps of CoMSIA, where compounds 18 and 23 were not outliers.
The outlier compounds in CoMSIA were 40 and 41, for which the model predicts greater activity
than the real one. This imprecision may be because, in the case of compound 40, it positions a
sulfonamide group towards the magenta polyhedral of the H-bond acceptor map, which is favorable
for activity. However, this group falls into the yellow region of the steric map, but the greater
contribution of the H-bond acceptor potential to the activity overestimates the predicted activity. In the
case of compound 41, the overestimation of the biological activity value may be due to the reduction
in the electronic density of the benzene ring, given by the thiourea group, which has the highest
percentage of contribution to biological activity.
2.4. Applicability Domain
The applicability domain (AD) is a theoretical region in chemical space encompassing both
the model descriptors and modeled response, which allows one to estimate the uncertainty in the
prediction of a compound based on how similar it is to the training compounds employed in the model
development. In this work, we used the method developed by Roy et al. [34] for the determination of
AD. This method is based on the basic theory of the standardization approach.
The calculation was carried out using the free application available on the author’s page, after
which it was obtained that all compounds were within the domain of applicability, except compound 18.
This reinforces what was described in the previous section, that alkylation of the urea connector could
result in significant changes in receptor binding. For this reason, none of the designed compounds
(see next section) included alkyl groups in the urea connector.
2.5. Design of Novel Derivatives
Based on the information provided by CoMFA and CoMSIA, we have designed a series of
structures of the aryloxypropanolamine type. In Table 5, we present the best derivatives with their
predicted pEC50 value by the best model (CoMSIA, r2 = 0.918). The first proposed molecule 1x was as
active as compound 16 (pEC50 = 7.208). The other structures (2x–12x) are more active than compound
16. The best candidates are compounds 3x (pEC50 = 8.561) and 7x (pEC50 = 8.520). The presence
of polar functions like OH, NH2, and F at position 5 of the imidazole ring yielded good candidates.
Other interesting proposals are the replacement of imidazole with a benzimidazole ring (comp. 9x–12x),
in which the presence of polar functions improves the activity.
3. Materials and Methods
3.1. Selection of Conformers and Molecular Alignment
CoMFA and CoMSIA studies were performed with Sybyl X-1.2 software (1.2, Tripos International,
St. Louis, MS, USA) installed in a Windows 10 environment on a PC with an Intel Core i7 CPU. To acquire
the best conformers for each molecule, every compound was drawn in ChemDraw and subjected to a
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preliminary geometry optimization using MM2 molecular mechanics as is implemented in ChemBio3D
software (15.1.0, PerkinElmer, Waltham, MA, USA). Following this, the structure of compound 16 (the
most active of the series) was further minimized by quantum mechanics using the DFT B3LYP/6.311+g**
method in Gaussian software (09, Gaussian Inc., Wallingford, CT, USA). This structure was used as
a template for the alignment. The mol2 structures were imported to Sybyl and MMFF94 charges
were assigned to each atom. The minimized structures were superimposed by the atom-by-atom fit
method choosing the aryloxypropanolamine nucleus as the common scaffold for alignment (Figure 5).
In addition, a minimization was carried out based on the Powell method [35] (as implemented in Sybyl,
Figure S1 in the Supplementary Material). However, the statistical results were much lower than those
reported by the method used in this manuscript (Table S3 in the Supplementary Material).Molecules 2018, 23, x FOR PEER REVIEW  12 of 20 
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were randomly extracted from the range of 6–8 logarithmic units of pEC50, while a smaller number
were randomly selected from the range of 4–6 logarithmic units. Several test set groups were evaluated.
For the construction of the final models, the test set that generated the highest r2 value in each case
(CoMFA and CoMSIA) was finally selected. The distribution of pEC50 values for the whole set, the
training set, and the test set is shown in Figure 6. In all three cases, the biological activity followed a
Gaussian distribution. The range of the biological activities spans 3.5 log units, from 3.89 to 7.37.Molecules 2018, 23, x FOR PEER REVIEW  13 of 20 
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column filter value of 2.0 to speed up the analysis and reduce the noise. The q2, which is a measure of
the internal quality of the models, was obtained according to the following Equation (1):
q2 = 1− ∑(yi − ypred)
2
∑(yi − y)2 (1)
where yi, y, and ypred are observed, mean, and predicted activity in the training set, respectively.
3.5. External Validation
The models were subjected to external validation criteria according to the proposed test by
Golbraikh and Tropsha [31,32], which considers a QSAR model predictive, if the following conditions
are satisfied:
q2 > 0.5 (2)
r2 > 0.6 (3)(
r2 − r20
)
r2
< 0.1 or
(
r2 − r′20
)
r2
< 0.1 (4)
0.85 ≤ k ≤ 1.15 or 0.85 ≤ k’ ≤ 1.15 (5)∣∣∣r20 − r′20∣∣∣ < 0.3 (6)
It has been demonstrated [31] that all of the above criteria are indeed necessary to adequately
assess the predictive ability of a QSAR model.
Furthermore, the external predictive power of the developed 3D-QSAR models using the test set
was examined by considering r2m metrics as shown below [37]:
r2m = r
2(1−
∣∣∣∣√r2 − r20∣∣∣∣) (7)
where r2 and r20 are the squared correlation coefficients between the observed and predicted activities
of the test set with and without the (0,0) intercept, respectively. For a significant external model
validation, the value of r2m should be greater than 0.5.
3.6. Applicability Domain Calculation
The AD was evaluated based on the simple standardization method reported by Roy et al. [34].
First, each descriptor “i” for each compound “k” is standardized (Sik). Every compound must have
a maximum value [Si]max(k) ≤ 3. In the case that [Si]max(k) > 3 and its minimum value [si]min(k) < 3,
then the Snew(k) parameter must be calculated and has to fulfill the condition: Snew(k) = Sk + 1.28× σSk ,
where Sk is the mean of Sik values for compound k and σSk is the standard deviation for such values.
The software is available free of charge on the authors’ website: http://dtclab.webs.com/software-tools
and http://teqip.jdvu.ac.in/QSAR_Tools/.
4. Conclusions
In the present article, we presented the construction of two QSAR models in aryloxypropanolamines
with selective potency for the β3-AR. The CoMFA and CoMSIA models presented good internal
(q2 = 0.537 and 0.669 for CoMFA and CoMSIA, respectively) and external (r2 = 0.865 and 0.918 for
CoMFA and CoMSIA, respectively) validation. The models were further validated following the criteria
given by Tropsha and Roy [31,32,37], and were determined to be statistically reliable and robust. In both
models, there was an equilibrium among the steric, electrostatic, hydrophobic, H-bond acceptor, and
H-bond donor contribution to the activity. With this information, a new series of compounds was
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designed. The predicted biological activity for the new derivatives is high and, in general, the presence
of polar groups and cycles like the benzimidazole ring on the RHS are predicted to improve activity.
This could be due the presence of polar functions may be important for interaction with the Arg315
residue, and aromatic rings may establish pi-stacking interactions with a Phe198 residue as it is
reported in literature [38].
Taking into account the information derived from the CoMFA and CoMSIA studies, we have
summarized the principal structure-activity relationships for the studies series of compounds in
Figure 7. This information will be useful for the design of new compounds with promising therapeutic
applications in several pathological disorders such as obesity, diabetes, OAB, depression, and cancer.
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